Status:

TERMINATED

Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy

Lead Sponsor:

Agennix

Conditions:

Carcinoma, Non-small Cell Lung

Lung Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

PURPOSE: This trial is designed to compare the combination of the investigational oral cytotoxic drug, satraplatin, and radiation therapy for patients with locally advanced Non-Small Cell Lung Cancer ...

Eligibility Criteria

Inclusion

  • Locally advanced or medically inoperable NSCLC (stage II or III)
  • ECOG performance status score 0-2
  • Adequate bone marrow, liver, and pulmonary functions
  • Life expectancy \> three months.

Exclusion

  • Prior malignancy
  • Serious concurrent uncontrolled medical disorder.
  • Uncontrolled or significant cardiovascular disease
  • History of mastectomy
  • Pregnant or breast-feeding patients are not eligible
  • Prior radiotherapy to the primary tumor site or cytotoxic chemotherapy

Key Trial Info

Start Date :

August 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2009

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT00093132

Start Date

August 1 2004

End Date

February 1 2009

Last Update

August 17 2012

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Southwestern Medical Center

Dallas, Texas, United States, 75390